# ALA-HIST IR- dexbrompheniramine maleate tablet Poly Pharmaceuticals, Inc.

-----

## ALA-HIST IR 2 mg Tablets

## **Drug Facts**

### **Active ingredients**

(in each tablet)

Dexbrompheniramine Maleate 2 mg

#### **Purpose**

**Antihistamine** 

#### Uses

Temporarily relieves these symptoms due to hay fever (allergic rhinitis) or upper respiratory allergies:

- runny nose
- sneezing
- itching of the nose or throat
- itchy, watery eyes

## Warnings

## Ask a doctor before use if you have

- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- trouble urinating due to enlargement of the prostate gland

**Ask a doctor or pharmacist before use if you are** taking sedatives or tranquilizers.

When using this product

- excitability may occur, especially in children
- may cause drowsiness
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase the drowsiness effect
- use caution when driving a motor vehicle or operating machinery

**If pregnant or breast-feeding,** ask a health professional before use.

## Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center right away.

#### **Directions**

·	
Adults and children	1 tablet every 4 to 6
12 years of age and	hours, not to exceed
over:	6 tablets in 24 hours.
Children 6 to under	1/2 tablet every 4 to 6
12 years of age:	hours, not to exceed
	3 tablets in 24 hours.
Children under 6	Consult a doctor.
years of age:	

#### Other information

Store at 15° - 30°C (59° - 86°F).

Supplied in a tight, light-resistant container with a child-resistant cap.

Contains color additives including FD&C Yellow No. 5 (tartrazine).

Ala-Hist IR Tablets are dark green caplet shaped, scored tablets, debossed "Poly" bisect "783" on one side and plain on the other.

## **Inactive ingredients**

colloidal silicon dioxide, croscarmellose sodium, dibasic calcium phosphate dihydrate, FD&C Blue #1 aluminum lake, FD&C Yellow #5 aluminum lake, magnesium stearate, and silicified microcrystalline cellulose.

#### **Questions?**

Call 1-800-882-1041

#### Manufactured for:

Poly Pharmaceuticals Quitman, MS 39355

Rev. 02/12

## **Product Packaging**

The packaging below represents the labeling currently used.

Principal display panel and side panel for 60 tablets label:

NDC 50991-783-60

**ALA-HIST IR** 

2 mg Tablets

**Antihistamine** 

Each tablet contains:

Dexbrompheniramine Maleate......2 mg

60 Tablets

Usual Dosage: See product foldout for full

prescribing information

Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing.

KEEP THIS AND ALL DRUGS OUT OF

REACH OF CHILDREN.


Store at controlled room temperature 15°-30°C

(59°-86°F).

Manufactured for:

Poly Pharmaceuticals

Rev. 02/12



#### **ALA-HIST IR**

dexbrompheniramine maleate tablet

Product Information			
Product Type	HUMAN OTC DRUG	Item Code (Source)	NDC:50991-783
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name	<b>Basis of Strength</b>	Strength	
<b>DEXBROMPHENIRAMINE MALEATE</b> (UNII: BPA9UT29BS) (DEXBROMPHENIRAMINE - UNII:75T64B71RP)	DEXBROMPHENIRAMINE MALEATE	2 mg	

Inactive Ingredients			
Ingredient Name	Strength		
CALCIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: O7TSZ97GEP)			
SILICON DIOXIDE (UNII: ETJ7Z6XBU4)			
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			

Product Characteristics			
Color	green (dark green)	Score	2 pieces
Shape	OVAL	Size	11mm
Flavor		Imprint Code	Poly;783
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:50991- 783-02	12 in 1 CARTON	08/22/2011	
1		1 in 1 BLISTER PACK; Type 0: Not a Combination Product		
2	NDC:50991- 783-60	60 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	08/22/2011	

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC Monograph Drug	M012	08/22/2011	

## **Labeler -** Poly Pharmaceuticals, Inc. (198449894)

Revised: 7/2024 Poly Pharmaceuticals, Inc.